T-Cell Receptor (TCR) Therapy- Executive Report 2020
$3,000.00 – $9,000.00
A Comprehensive Review on TCR Cell Therapy by Pipeline Analysis, Emerging Players having Innovative Portfolio, Commercial Assessment of Developmental Activities, Therapeutic Portfolio Assessment, Objective Assessment of Unmet Needs, Future Perspectives, and Technological Advancements to make informed R&D related decisions, modify therapeutic portfolio strategies, identify growth opportunities, strengthen or expand business by gaining extensive view.
Description
Mellalta, “T-Cell Receptor Therapies (TCR) – Executive Report”, provides comprehensive insights about pipeline drugs across T-Cell therapies, Deals Assessments, Collaborations & Market Opportunities.
T-cell receptor–engineered T-cell therapy and chimeric antigen receptor T-cell therapy are 2 types of adoptive T-cell therapy that genetically modify natural T cells to treat cancers. Although chimeric antigen receptor T-cell therapy has yielded remarkable efficacy for hematological malignancies of the B-cell lineages, most solid tumors fail to respond significantly to chimeric antigen receptor T cells. T-cell receptor–engineered T-cell therapy, on the other hand, has shown unprecedented promise in treating solid tumors and has attracted growing interest. Overall, TCR-T-cell therapy has been evolving rapidly and has become a promising strategy against various types of cancer, especially against solid tumors. Probably, this new approach can change the scenario of future cancer treatments.
There are 30+ active companies dealing with TCR-T Cell Therapy. Out of 30+, there are 10+ leading companies with 90+ active products in different clinical stages of development. Several major players such as Gilead Sciences, Takara Bio, Cell Medica, Immunocore, Medigene and Immatics US etc. are involved in the pipeline. Also, various academic institutes such as National Cancer Institute (NCI), National Institutes of Health (NIH) are also involved in the development of TCR-T Cell therapy. From last few years, various companies and institutes are collaborating for developing TCR-T Cell therapies. There are many emerging firms in TCR-T Cell therapy segment, which are seeking for collaborative development opportunities for the maximization of their technology and business platform.
Key Highlights of The Report
- TCR Therapies-Companies Collaboration
- TCR Therapies-Licensing & Acquisitions
- TCR therapies -Funding Details
- TCR Therapies -Company & Product Profilings
- TCR Therapies-Products Assessments [Clinical Trials, MOA, Indications, Clinical Trials Results]
Table of Contents
1 | Executive Summary | 3 |
Key findings | 3 | |
2 | T-cell receptor (TCR)-Target Background | 11 |
Introduction | 11 | |
Structural characteristics of the TCR | 11 | |
3 | TCR Therapies – Mellalta’s Analytical Perspective | 14 |
In-depth Commercial Assessment | 14 | |
TCR Therapies – Companies collaborations, Licensing, Acquisition–Deal Value Trends | 14 | |
Year-wise Company-Company Collaborations | 27 | |
Company-Academia Collaborations | 27 | |
TCR – Acquisitions Analysis | 33 | |
TCR Licensing Deals | 34 | |
TCR – Funding Details | 35 | |
TCR Technologies for Future Pipeline development | 37 | |
Other TCR Technologies | 37 | |
TCR Target Discover Platforms | 38 | |
TCR Engineered Allogeneic T-Cells Technology | 40 | |
4 | KOL and Industry Views | 42 |
Potential of TCR therapy in lung cancer? | 42 | |
What are some of the shortcomings, in general, of immunotherapy? | 42 | |
Current limitations in immunotherapy? | 42 | |
Major challenges in developing clinical trials with this TCR technology? | 43 | |
5 | Pipeline Therapeutics | 44 |
Active Products | 44 | |
Total Products for TCR immunotherapy by Stage | 45 | |
Mid-Stage Products (Phase II) | 46 | |
Comparative Analysis | 46 | |
Early-Stage Products (Phase I and IND) | 47 | |
Comparative Analysis | 47 | |
Pre-clinical and Discovery Stage Products | 49 | |
Comparative Analysis | 49 | |
Inactive Products | 51 | |
6 | Therapeutic Assessment | 52 |
Assessment by Product Type | 52 | |
Assessment by Stage and Product type | 53 | |
Assessment by Therapy Area | 54 | |
Assessment by Stage and Therapy Area | 55 | |
7 | Company Chapters | 56 |
Gilead Sciences | 56 | |
Product Development Activities | 56 | |
KITE-439: Gilead Sciences | 59 | |
SSX-2: Gilead Sciences | 60 | |
KRAS: Gilead Sciences | 62 | |
Neoantigens: Gilead Sciences | 63 | |
KITE-718: Gilead Sciences | 64 | |
HPV-16 E6 & E7: Gilead Sciences | 66 | |
MAGE A3 TCR: Gilead Sciences | 70 | |
MAGE A3/A6 TCR: Gilead Sciences | 74 | |
Adaptimmune | 77 | |
Product Development Activities | 78 | |
ADP-A2M10: Adaptimmune | 81 | |
ADP-A2M4: Adaptimmune | 83 | |
ADP-A2AFP: Adaptimmune | 89 | |
GlaxoSmithKline | 92 | |
Product Development Activities | 92 | |
GSK 3377794: GlaxoSmithKline | 94 | |
Altor BioScience | 97 | |
Product Development Activities | 97 | |
ALT-801: Altor BioScience | 99 | |
TCR2 Therapeutics | 103 | |
Product Development Activities | 103 | |
TC-210: TCR2 Therapeutics | 106 | |
TC-220: TCR2 Therapeutics | 110 | |
TC-110: TCR2 Therapeutics | 112 | |
TC-310: TCR2 Therapeutics | 115 | |
TC-410: TCR2 Therapeutics | 116 | |
China Immunotech | 117 | |
Product Development Activities | 117 | |
EBV TCR-T: China Immunotech | 117 | |
Takara Bio | 120 | |
Product Development Activities | 120 | |
TBI 1301: Takara Bio | 123 | |
WT1-specific TCR-T cells: Takara | 126 | |
Immatics US | 130 | |
Product Development Activities | 130 | |
IMA101: Immatics | 133 | |
IMA201: Immatics US | 135 | |
IMA202: Immatics US | 137 | |
IMA203: Immatics US | 139 | |
IMA204: Immatics | 141 | |
Multiple Programs- ACTengine: Immatics | 141 | |
IMA301: Immatics US | 144 | |
IMA401: Immatics | 146 | |
IMA402: Immatics | 147 | |
IMA403: Immatics | 147 | |
Multiple Programs- TCER/DuoBody: Immatics | 148 | |
Multiple Programs- TCER/BITE: Immatics | 149 | |
BioNTech | 150 | |
Product Development Activities | 150 | |
Individualized TCR: BioNTech | 154 | |
Individualized TCR: BioNTech | 155 | |
Lion TCR | 156 | |
Product Development Activities | 156 | |
TCR Therapy for Hepatocellular carcinoma (HCC) Recurrence Post-Liver Transplantation: Lion TCR | 158 | |
TCR Redirected T Cells for the treatment of Hepatocellular carcinoma Recurrence Post-Liver Transplantation: Lion TCR | 160 | |
TCR Therapy for the treatment of HCC Recurrence Post-Liver Resection: Lion TCR | 162 | |
LioCyx: Lion TCR | 163 | |
TCR therapy for Chronic HBV Infection: Lion TCR | 165 | |
TCR therapy for EBV-related Nasopharyngeal Carcinoma: Lion TCR | 166 | |
TCR therapy for Post-Transplant Lymphoproliferative Disorders: Lion TCR | 167 | |
Cell Medica | 168 | |
Product Development Activities | 168 | |
CMD-602: Cell Medica | 171 | |
Baltaleucel-T: Cell Medica | 173 | |
Bellicum Pharmaceuticals | 176 | |
Product Development Activities | 176 | |
BPX-701: Bellicum Pharmaceuticals | 178 | |
Tmunity Therapeutics | 180 | |
Product Development Activities | 180 | |
NY-ESO1 TCR-T: Tmunity Therapeutics | 182 | |
H3.3K27M TCR: Tmunity Therapeutics | 183 | |
Immunocore | 184 | |
Product Development Activities | 184 | |
IMCgp100: Immunocore | 190 | |
IMCgp100 checkpoint combination: Immunocore | 194 | |
IMC-C103C: Immunocore | 196 | |
IMC-F106C: Immunocore | 198 | |
IMC-G107C: Immunocore | 199 | |
Additional oncology programs: Immunocore | 200 | |
Partnered oncology programs: Immunocore | 201 | |
GSK1 (IMCnyeso): Immunocore | 202 | |
Infectious Disease Programs: Immunocore | 204 | |
Autoimmune Programs: Immunocore | 205 | |
Xiangxue Life Sciences (XLifeSc) | 206 | |
Product Development Activities | 206 | |
TAEST16001: Xiangxue Life Sciences/ Athenex | 208 | |
TAEST-xx1: Xiangxue Life Sciences | 211 | |
TAEST-xx2: Xiangxue Life Sciences | 212 | |
TAEST-xx3: Xiangxue Life Sciences | 213 | |
TAEST-xx4: Xiangxue Life Sciences | 214 | |
TAEST-xx5: Xiangxue Life Sciences | 215 | |
TAEST-xx6: Xiangxue Life Sciences | 216 | |
Ziopharm | 217 | |
Product Development Activities | 217 | |
TCR Sleeping Beauty Neoantigens: Ziopharm | 219 | |
Guangzhou FineImmune Biotechnology | 221 | |
Tumor-specific TCR-T cells: Guangzhou FineImmune Biotechnology | 221 | |
Juno Therapeutics (A Celgene Company) | 223 | |
Product Development Activities | 223 | |
JTCR 016: Juno Therapeutics | 225 | |
Medigene | 228 | |
Product Development Activities | 228 | |
MDG1011: Medigene | 232 | |
MDG1021: Medigene | 235 | |
TCR Bluebird bio 1: Medigene | 236 | |
TCR Cytovant: Medigene | 238 | |
TCR-IIT: Medigene | 239 | |
Tactiva Therapeutics | 240 | |
Product Development Activities | 240 | |
T-cell cancer immunotherapies Research program: Tactiva Therapeutics (Pre-clinical) | 241 | |
Zelluna Immunotherapy | 243 | |
Product Development Activities | 243 | |
ZI-H04: Zelluna Immunotherapy | 245 | |
ZI-HX: Zelluna Immunotherapy | 248 | |
TCR-T-X: Zelluna Immunotherapy | 249 | |
ZI-NK-T01: Zelluna Immunotherapy | 250 | |
ZI-NK-HX: Zelluna Immunotherapy | 251 | |
ZI-NK-X: Zelluna Immunotherapy | 251 | |
Unum Therapeutics | 253 | |
Product Development Activities | 253 | |
ACTR707 + Rituximab: Unum Therapeutics | 255 | |
ACTR087 + rituximab: Unum Therapeutics | 257 | |
ACTR707 + Trastuzumab: Unum Therapeutics | 259 | |
ACTR087 + SEA-BCMA: Unum Therapeutics | 261 | |
Artielle ImmunoTherapeutics | 263 | |
Product Development Activities | 263 | |
RTL1000: Artielle ImmunoTherapeutics | 264 | |
AgenTus (Subsidiary of Agenus) | 266 | |
Product Development Activities | 266 | |
AgenTus NY-ESO-1 TCRs: AgenTus | 267 | |
AGENt 04002: AgenTus | 270 | |
TCRCure Biotech | 274 | |
Product Development Activities | 274 | |
HPV E6-specific TCR-T cells: TCRCure Biotech | 275 | |
Pact Pharma | 277 | |
Product Development Activities | 277 | |
NeoTCR-P1 adoptive cell therapy: Pact Pharma | 279 | |
TScan Therapeutics | 285 | |
Product Development Activities | 285 | |
TSC-100: TScan Therapeutics | 286 | |
TSC-200: TScan Therapeutics | 287 | |
Cellular Biomedicine Group | 288 | |
Product Development Activities | 288 | |
AFP TCR-T: Cellular Biomedicine Group | 288 | |
Bluebird Biosciences | 290 | |
Product Development Activities | 290 | |
MCC1 TCR: Bluebird Biosciences | 290 | |
Gritstone Oncology | 292 | |
Product Development Activities | 292 | |
Cancer Research programme: Gritstone Oncology | 293 | |
8 | Future Prospective | 294 |
9 | Appendix | 295 |
10 | Unmet Needs | 310 |
11 | Disclaimer | 311 |
12 | About Mellalta | 311 |
List of Tables
Table 3.1: TCR Therapies companies collaborations, Licensing, Acquisition – Deal Value Trends, 2013-2019 | 14 |
Table 3.2: Company-Academia Collaborations | 27 |
Table 3.3: TCR Acquisition Analysis | 33 |
Table 3.4: TCR Licensing Deals | 34 |
Table 3.5: Funding Details | 35 |
Table 3.6 Other TCR Technologies | 37 |
Table 3.7: Technologies for Discovery of TCRs Targets | 38 |
Table 3.8 TCR Engineered Allogeneic T-Cells Technology | 40 |
Table 5.1: Total Products for TCR Immunotherapy by Stage | 45 |
Table 5.2: Mid Stage Products (Phase II) | 46 |
Table 5.3: Early Stage Products (Phase I and IND) | 47 |
Table 5.4: Pre-clinical and Discovery Stage Products | 49 |
Table 5.5: Inactive Products (Dormant and Discontinued) | 51 |
Table 6.1: Assessment by Product Type | 52 |
Table 6.2: Assessment by Stage and Product type | 53 |
Table 6.3: Assessment by Therapy area | 54 |
Table 6.4: Assessment by Stage and Therapy Area | 55 |
List of Figures
Figure 2.1: TCR protein and gene structure | 12 |
Figure 2.2: Gene rearrangement at the tr loci. | 13 |
Figure 3.1: TCR Therapies companies collaborations, Licensing, Acquisition – Deal Value Trends, 2013-2019 | 14 |
Figure 3.2: TCR Year-wise Company-Company Collaborations, 2013-2019 | 27 |
Figure 5.1: Total Products for TCR Immunotherapy by Companies | 44 |
Figure5.2: Total Products for TCR Immunotherapy by Stage | 45 |
Figure5.3: Mid Stage Products (Phase II) | 46 |
Figure5.4: Early Stage Products (Phase I and IND) | 47 |
Figure 5.5: Pre-clinical and Discovery Stage Products | 49 |
Figure6.1: Assessment by Product Type | 52 |
Figure6.2: Assessment by Stage and Product type | 53 |
Figure6.3: Assessment by Therapy area | 54 |
Figure 6.4: Assessment by Stage and Therapy Area | 55 |
Figure 7.1: siTCR vector technology | 120 |
Figure 7.2: Mode of action of siTCR based therapy | 121 |
Figure 7.3: TCR-T cell technology | 157 |
Figure7.4: Dominant T cell receptor (dTCR) technology | 170 |
Figure7.5: CaspaCIDe Technology | 176 |
Figure7.6: T cell Receptor Technology | 223 |
Figure 7.7: ImPACT Isolation Technology | 277 |
Figure 7.8: ImPACT Isolation Technology | 277 |
Figure 9.1: Size and composition of the pre-selection, naive and antigen-experienced repertoires. | 296 |
Figure 9.2: Skewing of the TCR repertoire in human disease. | 299 |
Figure 9.3: Process of TCR-engineered T cells therapy | 303 |
Figure 9.4: TCR Signalling | 305 |
Figure 9.5:Three typical procedures to obtain TCR sequence | 306 |